SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Avadel AVDL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DiB who wrote (88)10/21/2003 7:37:56 AM
From: Arthur Radley  Read Replies (1) of 240
 
Dib, I have no idea other than the fact this is a low revenue projected drug as the generic competition has taken the majority of the market from GSK and maybe they just figured it wasn't worth the effort to try and get the market back. It appears the total market was $200M and with newer drugs, probably even the generics would lose market revenue.
Regardless...very disappointing turn of events. It was interesting that FLML did reveal the other drug they are working on with GSK...this had been an unnannouced project as to what drug was involved. This gives me hope that GSK hasn't turned down the FLML delivery system in total.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News